Crossmark

A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Crossref DOI link: https://doi.org/10.1186/s12885-021-08005-1

Published Online: 2021-03-24

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kuo, Chih-Hsi Scott

Tung, Pi-Hung

Huang, Allen Chung-Cheng

Wang, Chin-Chou https://orcid.org/0000-0003-2932-751X
Chang, John Wen-Cheng

Liu, Chien-Ying

Chung, Fu-Tsai

Fang, Yueh-Fu

Guo, Yi-Ke

Yang, Cheng-Ta
Funding

Funding for this research was provided by:

Chang Gung Medical Foundation (CORPG3J0331)
License Information

Text and Data Mining valid from 2021-03-24

Version of Record valid from 2021-03-24
More Information

Article History

Received: 4 October 2020

Accepted: 3 March 2021

First Online: 24 March 2021

Declarations

:

: The study was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki. The Ethics Committee of Chang Gung Memorial Hospital approved the study and granted permission for the access of Chang Gung Research Database and the written informed consents were provided by all study participants.

: Not applicable.

: None of the authors have any conflict of interest to disclose.

Document is current

Any future updates will be listed below